OR WAIT null SECS
© 2024 MJH Life Sciences™ and BioPharm International. All rights reserved.
KBI Biopharma acquires Merck's microbial process development and manufacturing operations in Colorado.
KBI Biopharma (KBI), a contract development and manufacturing organization, has signed an agreement with Merck & Co., to acquire Merck’s microbial process development and manufacturing operations in Boulder, Colorado, effective May 1, 2014. Under the agreement, KBI will provide ongoing development and manufacturing services to Merck, as well as to third-party customers.
KBI will also continue to support other ongoing drug development programs for Merck from its two North Carolina facilities.
Source: KBI Biopharma
Related Content: